Durvalumab (Imfinzi): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects

Key takeaways

  • Durvalumab is a human IgG1κ monoclonal antibody targeting PD-L1.
  • It blocks PD-L1 interactions with PD-1 and CD80, restoring antitumor T-cell activity.
  • Durvalumab has established clinical uses across NSCLC, SCLC, biliary tract cancer, HCC, dMMR endometrial cancer, bladder cancer, and resectable gastric/GEJ adenocarcinoma.
  • The most common adult flat dose is 1,500 mg IV, with frequency determined by the indication and treatment phase.
  • PACIFIC established consolidation immunotherapy in unresectable stage III NSCLC.
  • ADRIATIC demonstrated significant survival benefits following chemoradiotherapy in limited-stage SCLC.
  • CASPIAN established durvalumab with platinum–etoposide in extensive-stage SCLC.
  • TOPAZ-1 supported durvalumab with gemcitabine–cisplatin in advanced biliary tract cancer.
  • HIMALAYA established the STRIDE regimen in unresectable HCC.
  • NIAGARA and VOLGA expanded perioperative treatment options in muscle-invasive bladder cancer.
  • MATTERHORN demonstrated the benefit of perioperative durvalumab with FLOT chemotherapy in resectable gastric/GEJ cancer.
  • Immune-mediated adverse reactions remain the principal safety concern.
  • Routine dose reductions are not recommended.

Durvalumab (Imfinzi) is a human IgG1κ monoclonal antibody targeting programmed death-ligand 1 (PD-L1), an inhibitory immune checkpoint protein expressed on tumor cells and immune cells within the tumor microenvironment. By preventing PD-L1 from interacting with PD-1 and CD80 (B7.1), durvalumab reduces inhibitory immune signaling and promotes T-cell-mediated antitumor activity.

Unlike conventional cytotoxic chemotherapy, durvalumab does not directly damage cancer-cell DNA or inhibit cell division. Instead, it enhances the immune system’s capacity to recognize and eliminate malignant cells.

Durvalumab belongs to the immune checkpoint inhibitor (ICI) class. It may be administered as monotherapy or combined with chemotherapy, tremelimumab, or other anticancer therapies, depending on the malignancy and treatment setting.

The FDA first approved durvalumab on May 1, 2017, for selected patients with advanced urothelial carcinoma. That historical indication was subsequently withdrawn. In 2018, the PACIFIC trial established durvalumab as consolidation immunotherapy following concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer (NSCLC).

Its clinical applications have expanded into small cell lung cancer (SCLC), biliary tract cancer, hepatocellular carcinoma (HCC), endometrial cancer, bladder cancer, and gastric or gastroesophageal junction adenocarcinoma.

Important regulatory developments during 2025–2026 include:

  • March 2025: FDA approval of perioperative durvalumab with gemcitabine–cisplatin for muscle-invasive bladder cancer.
  • November 2025: FDA approval of perioperative durvalumab with FLOT chemotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.
  • May 2026: FDA approval of durvalumab with Bacillus Calmette–Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer.
  • November 13, 2026: FDA approval of neoadjuvant durvalumab plus enfortumab vedotin, followed by adjuvant durvalumab after cystectomy, for patients with muscle-invasive bladder cancer who are ineligible for or refuse cisplatin-based chemotherapy.

These advances have expanded durvalumab from consolidation immunotherapy into neoadjuvant, perioperative, adjuvant, and first-line systemic treatment across multiple malignancies.

Key Facts

  • Generic name: Durvalumab
  • Brand name: Imfinzi
  • Drug class: Immune checkpoint inhibitor
  • Antibody type: Human IgG1κ monoclonal antibody with reduced Fc effector function
  • Molecular target: PD-L1 (CD274)
  • Mechanism: Blocks PD-L1 interactions with PD-1 and CD80, restoring antitumor T-cell activity
  • Initial FDA approval: May 1, 2017
  • Administration: Intravenous infusion
  • Common adult dose: 1,500 mg every four weeks, with indication-specific exceptions
  • Alternative dose: 10 mg/kg every two weeks in unresectable stage III NSCLC
  • Infusion duration: 60 minutes
  • Treatment duration: Indication-dependent, from a fixed postoperative course to treatment until progression
  • Major biomarkers: EGFR, ALK, dMMR, and selected disease-specific molecular characteristics
  • Landmark trials: PACIFIC, AEGEAN, POSEIDON, ADRIATIC, CASPIAN, TOPAZ-1, HIMALAYA, DUO-E, NIAGARA, POTOMAC, MATTERHORN, and VOLGA
  • Boxed warning: None
  • Major risks: Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, infusion reactions, and transplant complications
  • Monitoring: Liver function, renal function, thyroid function, blood glucose, pulmonary symptoms, and other immune-mediated adverse reactions
  • Elimination half-life: Approximately 18 days
  • Intravenous concentration: 50 mg/mL
  • Available vial strengths: 120 mg/2.4 mL and 500 mg/10 mL

What Is Durvalumab?

Durvalumab is a recombinant human monoclonal antibody designed to recognize and bind PD-L1, a cell-surface protein involved in regulating immune responses.

PD-L1 is expressed on selected malignant cells, antigen-presenting cells, and other cells within the tumor microenvironment.

Its physiological function includes protecting normal tissues from excessive immune activation.

When PD-L1 binds PD-1 on activated T lymphocytes, it suppresses T-cell receptor signaling, cytokine production, proliferation, and cytotoxic activity.

Malignant cells may exploit this pathway to escape immune surveillance.

Durvalumab blocks PD-L1 interactions with PD-1 and CD80, restoring immune activity in responsive antitumor T-cell populations.

Like atezolizumab and avelumab, durvalumab targets PD-L1.

In contrast, nivolumab, pembrolizumab, cemiplimab, and dostarlimab target the PD-1 receptor.

Durvalumab contains an engineered Fc region designed to minimize antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against PD-L1-expressing cells.

An important feature of durvalumab is its use alongside tremelimumab (Imjudo), an anti-CTLA-4 monoclonal antibody, allowing inhibition of two distinct immune checkpoint pathways.

What Is the Mechanism of Action of Durvalumab?

Durvalumab OncoDaily

1. PD-L1 Expression

Tumor cells and immune cells within the tumor microenvironment can express PD-L1.

Its expression may be increased by inflammatory signaling, including interferon-gamma.

PD-L1 contributes to immune escape by suppressing activated T cells.

2. PD-L1-Mediated T-Cell Inhibition

PD-L1 binds PD-1 receptors on activated T lymphocytes.

This interaction activates inhibitory intracellular signaling, including pathways involving SHP-2 phosphatase.

Consequently, T cells demonstrate reduced:

  • Proliferation
  • Cytokine secretion
  • Cytotoxic activity
  • Antitumor immune surveillance

PD-L1 can also interact with CD80 (B7.1), contributing to immune regulation.

3. Durvalumab Binds PD-L1

Durvalumab selectively binds PD-L1, preventing its interaction with PD-1 and CD80.

It does not directly block PD-1 interactions with PD-L2.

4. Restoration of T-Cell Activity

PD-L1 blockade reduces inhibitory signaling and enhances the function of responsive antitumor T lymphocytes.

This promotes:

  • T-cell proliferation
  • Cytokine production
  • Cytotoxic immune activity
  • Recognition of tumor-associated antigens

5. Immune-Mediated Tumor-Cell Killing

Activated cytotoxic CD8-positive T cells recognize malignant-cell antigens presented by major histocompatibility complex molecules.

They release perforin and granzymes, contributing to malignant-cell apoptosis and immune-mediated destruction.

6. Reduced Fc-Mediated Cytotoxicity

Durvalumab has an engineered IgG1 Fc region with reduced effector function.

This minimizes unwanted destruction of PD-L1-expressing immune cells.

Its primary therapeutic effect is therefore immune checkpoint blockade rather than direct antibody-mediated cell killing.

7. Durable Antitumor Immune Responses

Checkpoint inhibition may produce sustained immune surveillance and prolonged disease control.

However, resistance can occur through altered antigen presentation, impaired interferon signaling, T-cell exclusion, immunosuppressive immune populations, and alternative inhibitory checkpoints.

Overall mechanism:

Durvalumab → PD-L1 binding → inhibition of PD-L1/PD-1 and PD-L1/CD80 signaling → restoration of T-cell activity → enhanced antitumor immunity → malignant-cell destruction.

Why Is Durvalumab Combined With Tremelimumab?

Durvalumab and tremelimumab inhibit two complementary immune checkpoint pathways.

PD-L1 Blockade

Durvalumab reduces PD-L1-mediated immune suppression, supporting T-cell effector activity.

CTLA-4 Blockade

Tremelimumab blocks CTLA-4, an inhibitory receptor involved in regulating T-cell priming and activation.

Combined Immune Activation

Dual checkpoint inhibition may enhance antitumor activity by targeting both immune activation and effector-phase suppression.

This approach has established applications in unresectable HCC and selected patients with metastatic NSCLC.

However, combining PD-L1 and CTLA-4 inhibitors increases the potential for immune-mediated toxicity compared with PD-L1 monotherapy.

What Is the Recommended Dose of Durvalumab?

Durvalumab OncoDaily

Standard Adult Intravenous Dose

For many approved indications in patients weighing at least 30 kg, durvalumab is administered at:

1,500 mg IV every four weeks.

However, dosing differs according to the disease, treatment phase, and accompanying agents.

All doses are administered as a 60-minute intravenous infusion.

Unresectable Stage III Non-Small Cell Lung Cancer

Following concurrent platinum-based chemoradiotherapy without progression:

  • 10 mg/kg IV every two weeks, or
  • 1,500 mg IV every four weeks for patients weighing at least 30 kg.

Continue until disease progression, unacceptable toxicity, or 12 months.

Resectable Non-Small Cell Lung Cancer

For eligible adults with tumors measuring at least 4 cm and/or node-positive disease, without known EGFR mutations or ALK rearrangements:

Neoadjuvant treatment

Durvalumab 1,500 mg with platinum-based chemotherapy every three weeks for up to four cycles before surgery.

Adjuvant treatment

Durvalumab 1,500 mg every four weeks for up to 12 cycles following surgery.

Metastatic Non-Small Cell Lung Cancer

Durvalumab is administered with tremelimumab and platinum-doublet chemotherapy.

For patients weighing at least 30 kg:

  • Durvalumab: 1,500 mg every three weeks during four chemotherapy cycles.
  • Tremelimumab: 75 mg every three weeks during induction.
  • Maintenance: Durvalumab 1,500 mg every four weeks.
  • Additional tremelimumab: A fifth 75 mg dose at Week 16 according to the protocol.

Pemetrexed maintenance is incorporated for eligible non-squamous disease.

Limited-Stage Small Cell Lung Cancer

Following concurrent platinum-based chemotherapy and radiotherapy without progression:

Durvalumab 1,500 mg IV every four weeks.

Continue until progression, unacceptable toxicity, or 24 months.

Extensive-Stage Small Cell Lung Cancer

The standard first-line regimen includes:

  • Durvalumab: 1,500 mg IV every three weeks
  • Etoposide: Days 1–3
  • Carboplatin or cisplatin: Day 1

Treatment is repeated every 21 days for four cycles.

Following induction, continue durvalumab 1,500 mg every four weeks until progression or unacceptable toxicity.

Biliary Tract Cancer

For locally advanced or metastatic biliary tract cancer:

  • Durvalumab 1,500 mg every three weeks
  • Gemcitabine 1,000 mg/m² on Days 1 and 8
  • Cisplatin 25 mg/m² on Days 1 and 8

The regimen is repeated every 21 days for up to eight chemotherapy cycles.

Durvalumab is subsequently continued at 1,500 mg every four weeks.

Unresectable Hepatocellular Carcinoma

The STRIDE regimen consists of:

Initial treatment

  • Tremelimumab 300 mg IV once
  • Durvalumab 1,500 mg IV on the same day

Maintenance

Durvalumab 1,500 mg every four weeks until disease progression or unacceptable toxicity.

This regimen is commonly known as STRIDE: Single Tremelimumab Regular Interval Durvalumab.

Advanced or Recurrent dMMR Endometrial Cancer

During induction:

Durvalumab 1,120 mg IV every three weeks with carboplatin and paclitaxel for six cycles.

Following induction:

Durvalumab 1,500 mg IV every four weeks as maintenance.

The approved U.S. indication requires dMMR status.

BCG-Naïve High-Risk Non-Muscle-Invasive Bladder Cancer

Durvalumab is administered with intravesical BCG induction and maintenance.

Durvalumab 1,500 mg IV every four weeks for 13 cycles.

BCG follows its separate intravesical administration schedule.

Muscle-Invasive Bladder Cancer — Cisplatin-Eligible

The NIAGARA-based perioperative regimen includes:

Neoadjuvant treatment

Durvalumab 1,500 mg IV every three weeks with gemcitabine and cisplatin for four cycles.

Adjuvant treatment

Durvalumab 1,500 mg IV every four weeks for up to eight cycles following radical cystectomy.

Muscle-Invasive Bladder Cancer — Cisplatin-Ineligible or Cisplatin-Refusing

The November 2026 FDA approval established the VOLGA-based regimen of neoadjuvant durvalumab plus enfortumab vedotin, followed by adjuvant durvalumab after radical cystectomy.

The clinical trial administered neoadjuvant enfortumab vedotin with durvalumab over three 21-day cycles.

Important: The November 2026 supplemental prescribing information should be used to confirm the complete approved dosing instructions and perioperative treatment schedule; the older August 2026 label does not include this new indication.

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Durvalumab is combined with FLOT chemotherapy.

Neoadjuvant treatment

Durvalumab 1,500 mg every four weeks with FLOT for up to two cycles before surgery.

Adjuvant treatment

Durvalumab 1,500 mg every four weeks with FLOT for up to two cycles.

Then continue durvalumab 1,500 mg every four weeks for up to ten additional cycles.

Patients Weighing Less Than 30 kg

Weight-based dosing is recommended for patients weighing less than 30 kg, with schedules depending on the indication.

Commonly used label-defined doses include 20 mg/kg every three or four weeks, although some regimens use 10 or 15 mg/kg.

These are weight-based adjustments within adult indications, not evidence of routine pediatric approval.

Treatment Duration

Treatment duration is indication-specific.

  • Stage III NSCLC consolidation: Up to 12 months.
  • Limited-stage SCLC consolidation: Up to 24 months.
  • Advanced cancers: Usually until progression or unacceptable toxicity.
  • Perioperative treatment: Fixed numbers of neoadjuvant and adjuvant cycles.
  • High-risk NMIBC: 13 durvalumab cycles with BCG.

These schedules follow the U.S. prescribing information, with the additional November 2026 VOLGA approval noted separately.

How Should Durvalumab Be Administered?

Intravenous Infusion

Durvalumab is administered by intravenous infusion over 60 minutes.

It must not be administered as an intravenous push or bolus.

Preparation and Dilution

Imfinzi is supplied as a 50 mg/mL solution in single-dose vials.

Available strengths include:

  • 120 mg/2.4 mL
  • 500 mg/10 mL

The required dose is diluted using an appropriate infusion solution, including:

  • 0.9% sodium chloride
  • 5% dextrose

The diluted solution should be mixed gently without shaking.

The product should be protected from freezing and excessive agitation.

Administration With Chemotherapy

When durvalumab and chemotherapy are administered on the same day, durvalumab is generally given before chemotherapy.

When tremelimumab is included, tremelimumab is administered before durvalumab.

All medications should be prepared and administered separately according to their prescribing information.

Administration With BCG

For high-risk NMIBC, durvalumab is administered intravenously while BCG is administered intravesically.

If given on the same day, durvalumab is administered before BCG.

Premedication

Routine corticosteroid or antihistamine premedication is not generally required for durvalumab monotherapy.

Premedication may be considered for previous infusion reactions or according to the accompanying chemotherapy regimen.

Hospitalization

Routine hospitalization is not required.

Treatment is generally administered in an outpatient oncology setting with appropriate facilities for managing infusion reactions and immune-mediated toxicities.

What Should You Do If a Durvalumab Dose Is Missed?

If a scheduled infusion is missed:

  • Contact the treating oncology team.
  • Determine the reason for the interruption.
  • Reschedule treatment according to clinical circumstances.
  • Reassess any treatment-related toxicity before restarting.
  • Do not administer a double dose.

Durvalumab does not require routine dose escalation following a missed infusion.

For perioperative regimens, treatment interruptions should also be coordinated with the planned surgical schedule.

How Are Durvalumab Dose Modifications Managed?

Routine dose reductions are not recommended.

Immune-mediated adverse reactions are managed through temporary treatment interruption, systemic corticosteroids, additional immunosuppressive therapy when necessary, or permanent discontinuation.

Immune-Mediated Pneumonitis

Grade 2: Withhold durvalumab.

Grade 3–4: Permanently discontinue treatment.

Alternative causes of pulmonary symptoms, including infection, radiation pneumonitis, pulmonary embolism, and cancer progression, should be investigated.

Immune-Mediated Colitis

Grade 2–3 colitis generally requires treatment interruption.

Grade 4 colitis requires permanent discontinuation.

Systemic corticosteroids are commonly used for clinically significant cases.

Infliximab or vedolizumab may be considered for corticosteroid-refractory colitis after appropriate infectious evaluation.

Immune-Mediated Hepatitis

Treatment modification depends on AST, ALT, bilirubin, baseline hepatic function, and underlying liver disease.

Severe hepatitis may require permanent discontinuation.

Mycophenolate mofetil may be used for selected corticosteroid-refractory cases.

Immune-Mediated Endocrinopathies

Hypothyroidism, adrenal insufficiency, hypophysitis, and diabetes may require hormone replacement.

Treatment may be withheld until the patient is clinically stable.

Permanent discontinuation is not always necessary for endocrine dysfunction adequately controlled with replacement treatment.

Immune-Mediated Nephritis

Clinically significant creatinine elevation may require withholding durvalumab and administering corticosteroids.

Severe nephritis may require permanent discontinuation.

Immune-Mediated Myocarditis

Suspected myocarditis requires immediate treatment interruption and urgent cardiac assessment.

Confirmed clinically significant myocarditis generally requires permanent discontinuation and specialist management.

Infusion-Related Reactions

Mild or moderate infusion reactions may require slowing or interrupting the infusion.

Severe or life-threatening reactions require permanent discontinuation.

Combination-Specific Toxicity

When durvalumab is combined with tremelimumab, chemotherapy, or enfortumab vedotin, the accompanying drug may require separate dose modifications.

Treatment decisions should follow the individual product labels.

What Drug Interactions Are Important With Durvalumab?

CYP450-Metabolized Medications

Durvalumab is not primarily metabolized through hepatic cytochrome P450 enzymes.

Conventional CYP-mediated pharmacokinetic interactions are therefore not expected.

Corticosteroids

Systemic corticosteroids suppress immune activity.

Unnecessary baseline immunosuppression should generally be minimized when clinically feasible.

However, corticosteroids remain essential for managing clinically significant immune-mediated adverse reactions.

Immunosuppressive Agents

Concurrent immunosuppressive treatment may influence immune checkpoint inhibitor activity.

Careful assessment is particularly important in patients with autoimmune diseases or previous organ transplantation.

Tremelimumab

The combination may increase the incidence and severity of:

  • Immune-mediated colitis
  • Hepatitis
  • Endocrinopathies
  • Pneumonitis
  • Dermatological toxicity

Platinum-Based Chemotherapy

Combination treatment may increase:

  • Myelosuppression
  • Infection
  • Nausea and vomiting
  • Nephrotoxicity
  • Peripheral neuropathy
  • Electrolyte abnormalities

Enfortumab Vedotin

When durvalumab is combined with enfortumab vedotin, additional risks include:

  • Peripheral neuropathy
  • Severe dermatological reactions
  • Hyperglycemia
  • Ocular toxicity
  • Infusion and treatment-related complications

Intravesical BCG

BCG introduces risks of local urinary tract symptoms, fever, systemic BCG infection, and inflammatory complications.

The immunological toxicity profiles of durvalumab and BCG should be considered independently.

Does Durvalumab Require Dose Adjustment in Renal or Hepatic Impairment?

Renal Impairment

Population pharmacokinetic analyses have not demonstrated clinically significant changes in durvalumab exposure in patients with mild or moderate renal impairment.

Routine dose adjustment is generally unnecessary within the studied population.

Evidence in severe renal impairment remains more limited.

Patients receiving cisplatin require separate renal assessment because cisplatin-associated nephrotoxicity may influence chemotherapy eligibility.

Hepatic Impairment

Mild and moderate hepatic impairment have not demonstrated clinically meaningful effects on durvalumab pharmacokinetics.

Evidence in severe hepatic impairment remains limited.

In HCC, baseline cirrhosis, hepatic reserve, viral hepatitis, and portal hypertension should be assessed.

Treatment-emergent immune-mediated hepatitis must be differentiated from disease progression, biliary obstruction, and underlying hepatic dysfunction.

What Is the Pharmacokinetic Profile of Durvalumab?

Molecular Structure

Durvalumab is a human IgG1κ monoclonal antibody with an approximate molecular weight of 149 kDa.

Distribution

Estimated steady-state volume of distribution:

5.4 L

Elimination Half-Life

Approximately:

21 days

Clearance

Estimated steady-state clearance:

8 mL/hour

Metabolism

Durvalumab undergoes proteolytic degradation into small peptides and amino acids.

Its metabolism does not primarily involve cytochrome P450 enzymes.

Steady-State Exposure

Durvalumab demonstrates time-dependent clearance, which decreases during repeated treatment.

The change in clearance is not considered clinically meaningful for routine dosing.

Immunogenicity

Antidrug antibodies may develop during treatment.

Their clinical relevance depends on the study population, assay sensitivity, and effects on drug exposure.

The pharmacokinetic values above follow the August 2026 U.S. prescribing information.

What Are the Clinical Uses of Durvalumab?

Unresectable Stage III Non-Small Cell Lung Cancer

Durvalumab is approved as consolidation treatment for adults with unresectable stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Treatment is generally administered for up to 12 months.

The indication is supported by the PACIFIC trial.

Resectable Non-Small Cell Lung Cancer

Durvalumab is approved with platinum-based chemotherapy as neoadjuvant treatment, followed by adjuvant durvalumab after surgery.

Eligible patients have tumors measuring at least 4 cm and/or node-positive disease, without known EGFR mutations or ALK rearrangements.

The pivotal supporting study is AEGEAN.

Metastatic Non-Small Cell Lung Cancer

Durvalumab combined with tremelimumab and platinum-based chemotherapy is approved for adults with metastatic NSCLC without sensitizing EGFR mutations or ALK genomic aberrations.

The indication is supported by POSEIDON.

Limited-Stage Small Cell Lung Cancer

Durvalumab is approved as consolidation monotherapy following concurrent platinum-based chemoradiotherapy in patients without disease progression.

The ADRIATIC study demonstrated significant improvements in overall and progression-free survival.

Extensive-Stage Small Cell Lung Cancer

Durvalumab combined with platinum–etoposide is approved as first-line treatment for extensive-stage SCLC.

Durvalumab is continued as maintenance after induction chemotherapy.

The indication is supported by CASPIAN.

Biliary Tract Cancer

Durvalumab with gemcitabine and cisplatin is approved for locally advanced or metastatic biliary tract cancer.

Relevant malignancies include:

  • Intrahepatic cholangiocarcinoma
  • Extrahepatic cholangiocarcinoma
  • Gallbladder carcinoma

The TOPAZ-1 trial established the survival benefit of adding durvalumab to gemcitabine–cisplatin.

Unresectable Hepatocellular Carcinoma

Durvalumab combined with tremelimumab is approved for adults with unresectable HCC.

The STRIDE regimen provides a dual immune checkpoint treatment option.

The pivotal study is HIMALAYA.

Advanced or Recurrent dMMR Endometrial Cancer

Durvalumab is approved with carboplatin and paclitaxel followed by maintenance durvalumab for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.

The indication is supported by DUO-E.

High-Risk Non-Muscle-Invasive Bladder Cancer

Durvalumab combined with BCG is approved for adults with BCG-naïve, high-risk NMIBC.

The approval was based on the POTOMAC trial.

BCG-naïve status and the patient’s risk classification are important for treatment selection.

Muscle-Invasive Bladder Cancer

Durvalumab has two distinct perioperative treatment strategies.

Cisplatin-eligible patients

Durvalumab is combined with neoadjuvant gemcitabine–cisplatin, followed by radical cystectomy and adjuvant durvalumab.

This regimen is supported by NIAGARA.

Cisplatin-ineligible or cisplatin-refusing patients

Durvalumab is combined with neoadjuvant enfortumab vedotin, followed by radical cystectomy and adjuvant durvalumab.

The regimen is supported by VOLGA and received FDA approval in November 2026.

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Durvalumab is approved with perioperative FLOT chemotherapy, followed by adjuvant durvalumab monotherapy.

This indication is supported by MATTERHORN.

It represents an important expansion of immune checkpoint inhibition into the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

Historical Urothelial Carcinoma Indication

Durvalumab was initially approved in 2017 for selected patients with advanced urothelial carcinoma.

That accelerated approval was subsequently withdrawn.

It should not be confused with the newer perioperative and NMIBC indications.

What Molecular Testing Is Required Before Durvalumab?

PD-L1 Expression

PD-L1 expression may be assessed using immunohistochemistry.

However, PD-L1 positivity is not required for every durvalumab indication.

For example, the U.S. PACIFIC-based stage III NSCLC indication does not require a minimum PD-L1 threshold.

European regulatory requirements differ, with a PD-L1 tumor-cell expression threshold of at least 1% in the corresponding stage III NSCLC indication.

EGFR and ALK Testing

In NSCLC, molecular testing should identify actionable genomic alterations.

The perioperative and metastatic NSCLC indications have specific EGFR and ALK eligibility restrictions.

Broader molecular profiling remains important for selecting optimal systemic treatment.

Mismatch Repair Testing

For advanced or recurrent endometrial cancer, dMMR status must be established using an FDA-authorized test.

Mismatch repair proteins commonly assessed include:

  • MLH1
  • PMS2
  • MSH2
  • MSH6

Loss of expression may indicate mismatch repair deficiency.

Hepatocellular Carcinoma Assessment

Before treatment with durvalumab and tremelimumab, evaluate:

  • Hepatic reserve
  • Child–Pugh classification
  • Portal hypertension
  • Viral hepatitis status
  • Baseline liver function
  • Performance status

No universal PD-L1 biomarker threshold is required for the STRIDE regimen.

Biliary Tract Cancer Molecular Testing

Molecular profiling remains important in advanced biliary tract cancer.

Clinically actionable alterations may include:

  • FGFR2 fusions
  • IDH1 mutations
  • HER2 alterations
  • BRAF V600E mutations
  • MSI-H/dMMR status

These biomarkers guide subsequent targeted treatment options but are not mandatory eligibility requirements for durvalumab–gemcitabine–cisplatin.

Bladder Cancer Assessment

For MIBC, confirm histology, clinical stage, renal function, surgical eligibility, and cisplatin eligibility.

For NMIBC, confirm high-risk disease and BCG-naïve status.

Molecular biomarkers are being investigated in NIAGARA and VOLGA but do not replace the established eligibility criteria.

Baseline Clinical Evaluation

Before initiating durvalumab, assess:

  • Complete blood count
  • Renal function
  • Liver function
  • Thyroid function
  • Blood glucose
  • Autoimmune disease history
  • Previous transplantation
  • Prior thoracic irradiation
  • Performance status
  • Pregnancy status when relevant

What Did the Pivotal Clinical Trials Show?

Durvalumab OncoDaily

PACIFIC — Durvalumab After Chemoradiotherapy in Stage III NSCLC

PACIFIC (NCT02125461) was a randomized phase III trial involving 713 patients with unresectable stage III NSCLC who had not progressed following concurrent platinum-based chemoradiotherapy.

Patients received durvalumab or placebo for up to 12 months.

Median Overall Survival — Five-Year Follow-Up

  • Durvalumab: 47.5 months
  • Placebo: 29.1 months

Overall Survival Hazard Ratio

HR: 0.72 (95% CI, 0.59–0.89)

Five-Year Overall Survival

  • Durvalumab: 42.9%
  • Placebo: 33.4%

Median Progression-Free Survival

  • Durvalumab: 16.9 months
  • Placebo: 5.6 months

Progression-Free Survival Hazard Ratio

HR: 0.55 (95% CI, 0.45–0.68)

PACIFIC established durvalumab consolidation as an important standard treatment strategy following concurrent chemoradiotherapy in unresectable stage III NSCLC.

Read More: Stephen V. Liu Reflects on Overall Survival From PACIFIC-R by OncoDaily.

Watch More: PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC — OncLive.

AEGEAN — Perioperative Durvalumab in Resectable NSCLC

AEGEAN (NCT03800134) was a randomized phase III trial evaluating neoadjuvant durvalumab plus platinum-based chemotherapy, followed by adjuvant durvalumab, compared with chemotherapy and placebo.

The modified intention-to-treat efficacy population included 740 patients.

Event-Free Survival Hazard Ratio

HR: 0.68 (95% CI, 0.53–0.88)

P = 0.0039

Pathological Complete Response

  • Durvalumab combination: 17.2%
  • Control: 4.3%

Major Pathological Response

  • Durvalumab combination: 34%
  • Control: 14%

The results demonstrated significant improvements in event-free survival and pathological response, supporting perioperative durvalumab in selected resectable NSCLC.

POSEIDON — Durvalumab Plus Tremelimumab and Chemotherapy in Metastatic NSCLC

POSEIDON (NCT03164616) was a randomized phase III study comparing durvalumab plus tremelimumab and platinum-based chemotherapy with chemotherapy alone.

The pivotal efficacy comparison included 675 patients.

Median Overall Survival

  • Durvalumab combination: 14.0 months
  • Chemotherapy: 11.7 months

Overall Survival Hazard Ratio

HR: 0.77 (95% CI, 0.65–0.92)

P = 0.00304

Median Progression-Free Survival

  • Combination: 6.2 months
  • Chemotherapy: 4.8 months

Progression-Free Survival Hazard Ratio

HR: 0.72 (95% CI, 0.60–0.86)

Overall Response Rate

  • Combination: 39%
  • Chemotherapy: 24%

The findings supported dual checkpoint blockade with chemotherapy in eligible patients with metastatic NSCLC.

ADRIATIC — Consolidation Durvalumab in Limited-Stage SCLC

ADRIATIC (NCT03703297) was a randomized phase III trial evaluating consolidation durvalumab after concurrent chemoradiotherapy in limited-stage SCLC.

The primary durvalumab-versus-placebo comparison included 530 patients.

Median Overall Survival

  • Durvalumab: 55.9 months
  • Placebo: 33.4 months

Overall Survival Hazard Ratio

HR: 0.73 (95% CI, 0.57–0.93)

P = 0.0104

Median Progression-Free Survival

  • Durvalumab: 16.6 months
  • Placebo: 9.2 months

Progression-Free Survival Hazard Ratio

HR: 0.76 (95% CI, 0.61–0.95)

P = 0.0161

The study demonstrated significant improvements in overall and progression-free survival, establishing consolidation durvalumab as an important treatment for limited-stage SCLC following chemoradiotherapy.

CASPIAN — First-Line Durvalumab in Extensive-Stage SCLC

CASPIAN (NCT03043872) was a randomized phase III trial evaluating durvalumab plus platinum–etoposide compared with chemotherapy alone in previously untreated extensive-stage SCLC.

The relevant efficacy comparison included 537 patients.

Median Overall Survival

  • Durvalumab plus chemotherapy: 13.0 months
  • Chemotherapy alone: 10.3 months

Overall Survival Hazard Ratio

HR: 0.73 (95% CI, 0.59–0.91)

P = 0.0047

Median Progression-Free Survival

  • Durvalumab combination: 5.1 months
  • Chemotherapy: 5.4 months

Progression-Free Survival Hazard Ratio

HR: 0.78 (95% CI, 0.65–0.94)

Overall Response Rate

  • Durvalumab combination: 68%
  • Chemotherapy: 58%

Although median PFS was similar, durvalumab demonstrated improved overall survival, supporting its first-line use in extensive-stage SCLC.

Does Durvalumab Have CNS Activity?

Durvalumab-containing regimens may provide systemic antitumor benefit in selected patients with brain metastases, particularly NSCLC and SCLC.

Its mechanism primarily involves immune activation rather than direct targeting of a CNS-specific oncogenic driver.

Brain Metastases in NSCLC

Durvalumab-containing regimens have been studied in populations including selected patients with treated or stable brain metastases.

However, prospective intracranial efficacy evidence remains limited compared with CNS-active targeted therapies in molecularly selected NSCLC.

Brain Metastases in SCLC

SCLC carries a substantial risk of intracranial metastases.

Durvalumab is used in both limited-stage and extensive-stage SCLC but does not replace appropriate MRI surveillance or indicated brain-directed treatment.

Decisions regarding prophylactic cranial irradiation should be individualized.

Clinical Considerations

Treatment selection depends on:

  • Neurological symptoms
  • Number and size of intracranial lesions
  • Corticosteroid requirements
  • Previous brain radiotherapy
  • Extracranial disease control
  • Suitability for stereotactic radiosurgery or surgery

Durvalumab is not an established standard treatment for primary CNS malignancies such as glioblastoma.

Is Durvalumab FDA Approved?

Yes.

Durvalumab received its initial FDA approval in May 2017.

Important regulatory milestones include:

  • 2017: Initial advanced urothelial carcinoma approval, subsequently withdrawn.
  • 2018: Consolidation treatment for unresectable stage III NSCLC.
  • 2020: First-line extensive-stage SCLC.
  • 2022: Advanced biliary tract cancer, unresectable HCC with tremelimumab, and metastatic NSCLC with tremelimumab and chemotherapy.
  • 2024: Perioperative NSCLC, limited-stage SCLC consolidation, and dMMR advanced or recurrent endometrial cancer.
  • 2025: Perioperative muscle-invasive bladder cancer with gemcitabine–cisplatin and perioperative gastric/GEJ adenocarcinoma with FLOT.
  • May 2026: High-risk BCG-naïve NMIBC with BCG.
  • November 2026: Perioperative bladder cancer treatment with neoadjuvant enfortumab vedotin for patients ineligible for or refusing cisplatin.

Regulatory status differs by treatment setting, biomarker requirements, combination regimen, and geographical region.

What Is the Current Clinical Role of Durvalumab in 2026?

Consolidation Immunotherapy

Durvalumab remains a major treatment option following concurrent chemoradiotherapy in unresectable stage III NSCLC.

Its role has also expanded to limited-stage SCLC following chemoradiotherapy.

First-Line Chemoimmunotherapy

Durvalumab is used in selected patients with extensive-stage SCLC and advanced biliary tract cancer.

It may also be combined with tremelimumab and chemotherapy in metastatic NSCLC.

Dual Checkpoint Inhibition

The durvalumab–tremelimumab combination remains important in unresectable HCC and selected metastatic NSCLC.

Perioperative Immunotherapy

Durvalumab has established roles in resectable NSCLC, muscle-invasive bladder cancer, and gastric/GEJ adenocarcinoma.

Biomarker-Guided Treatment

dMMR testing is essential for its approved advanced or recurrent endometrial cancer indication.

Molecular profiling also informs patient selection in NSCLC and other malignancies.

Bladder-Preserving Treatment

Durvalumab with BCG introduces a systemic immunotherapy component to selected high-risk NMIBC treatment.

This application should not be confused with perioperative treatment for muscle-invasive disease.

What Are the Major Side Effects of Durvalumab?

Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions are the principal characteristic toxicities associated with durvalumab.

PD-L1 blockade may disrupt physiological immune tolerance, allowing activated immune cells to damage normal tissues.

These reactions may affect almost any organ system and can occur during treatment or after discontinuation.

Severe and fatal immune-mediated toxicities have been reported.

The risk of certain toxicities is increased when durvalumab is combined with tremelimumab.

Immune-Mediated Pneumonitis

Symptoms include:

  • New or worsening cough
  • Dyspnea
  • Hypoxia
  • Chest discomfort
  • Fever

Radiological findings may include ground-glass opacities, interstitial infiltrates, or organizing pneumonia.

Pneumonitis is particularly important in patients receiving durvalumab after thoracic chemoradiotherapy.

Differential diagnoses include radiation pneumonitis, infection, pulmonary embolism, and disease progression.

Immune-Mediated Colitis

Colitis may present with diarrhea, abdominal pain, gastrointestinal bleeding, fever, and dehydration.

Severe cases may result in bowel perforation.

The risk is particularly relevant when durvalumab is combined with tremelimumab.

Immune-Mediated Hepatitis

Possible manifestations include:

  • Elevated AST and ALT
  • Hyperbilirubinemia
  • Fatigue
  • Jaundice
  • Right upper quadrant discomfort

Hepatitis requires particular attention in patients with HCC, underlying cirrhosis, or biliary tract cancer.

Thyroid Dysfunction

Durvalumab may cause:

  • Hypothyroidism
  • Hyperthyroidism
  • Thyroiditis

Some patients experience transient thyrotoxicosis followed by hypothyroidism.

Long-term thyroid hormone replacement may be required.

Adrenal Insufficiency

Symptoms may include fatigue, hypotension, nausea, vomiting, hyponatremia, and hypoglycemia.

Severe cases may develop adrenal crisis, requiring emergency treatment.

Hypophysitis

Immune-mediated pituitary inflammation may cause ACTH, TSH, gonadotropin, and other hormone deficiencies.

Patients may present with headache, fatigue, hypotension, visual disturbances, or electrolyte abnormalities.

Type 1 Diabetes Mellitus

Durvalumab may cause immune-mediated pancreatic beta-cell injury.

Patients can develop insulin-dependent diabetes or present with diabetic ketoacidosis.

Immune-Mediated Nephritis

Possible findings include:

  • Increased serum creatinine
  • Acute kidney injury
  • Reduced glomerular filtration
  • Electrolyte abnormalities

Other causes, including dehydration, infection, obstruction, and cisplatin nephrotoxicity, should be investigated.

Dermatological Toxicity

Dermatological adverse reactions include:

  • Rash
  • Pruritus
  • Erythema
  • Dry skin
  • Inflammatory skin eruptions

Rare severe reactions include Stevens–Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome.

Immune-Mediated Myocarditis

Myocarditis is uncommon but potentially life-threatening.

Clinical manifestations include chest pain, dyspnea, palpitations, syncope, arrhythmias, elevated troponin, and heart failure.

Myocarditis may coexist with myositis or myasthenia gravis.

Suspected myocarditis requires immediate treatment interruption and urgent cardiac evaluation.

Neurological Toxicity

Potential complications include:

  • Myasthenia gravis
  • Guillain–Barré syndrome
  • Encephalitis
  • Myelitis
  • Peripheral neuropathy
  • Autoimmune neuropathies

New weakness, diplopia, swallowing difficulties, or neurological deficits require urgent assessment.

Infusion-Related Reactions

Symptoms may include fever, chills, rash, flushing, wheezing, hypotension, and dyspnea.

Severe or life-threatening reactions require permanent treatment discontinuation.

Transplant-Related Complications

Checkpoint inhibition may increase the risk of solid organ transplant rejection.

Serious and fatal complications, including graft-versus-host disease, have occurred in patients receiving allogeneic hematopoietic stem-cell transplantation before or after PD-1/PD-L1 blockade.

Chemotherapy-Associated Toxicity

When durvalumab is combined with cytotoxic chemotherapy, additional adverse reactions may include:

  • Neutropenia
  • Anemia
  • Thrombocytopenia
  • Infection
  • Nausea and vomiting
  • Alopecia
  • Peripheral neuropathy
  • Mucositis
  • Fatigue

Tremelimumab-Associated Toxicity

Combining durvalumab with tremelimumab increases the potential for immune-mediated complications, particularly:

  • Colitis
  • Hepatitis
  • Endocrinopathies
  • Dermatological toxicity

Enfortumab Vedotin-Associated Toxicity

Combination treatment may introduce additional:

  • Peripheral neuropathy
  • Severe skin reactions
  • Hyperglycemia
  • Ocular symptoms
  • Fatigue

These toxicities should be distinguished from immune-mediated adverse reactions associated with durvalumab.

BCG-Associated Toxicity

Intravesical BCG can cause:

  • Dysuria
  • Urinary frequency
  • Hematuria
  • Fever
  • Local inflammatory symptoms

Rare systemic BCG infections require urgent assessment.

Other Common Adverse Reactions

Frequently reported adverse reactions across durvalumab regimens include:

  • Fatigue
  • Nausea
  • Decreased appetite
  • Constipation
  • Diarrhea
  • Rash
  • Pruritus
  • Fever
  • Cough
  • Musculoskeletal pain

The frequency and severity vary by malignancy and accompanying treatment.

Embryo-Fetal Toxicity

Durvalumab may cause fetal harm.

Females of reproductive potential should use effective contraception during treatment and for at least three months after the last dose.

Breastfeeding is not recommended during treatment and for three months afterward.

Durvalumab OncoDaily

What Monitoring Is Required During Durvalumab Treatment?

Thyroid Function

Monitor TSH and free T4 at baseline and periodically throughout treatment.

Investigate symptoms of hypothyroidism, hyperthyroidism, or thyroiditis.

Adrenal and Pituitary Function

Assess morning cortisol, ACTH, electrolytes, and additional pituitary hormones when clinically indicated.

Unexplained fatigue, hypotension, hyponatremia, or headache should prompt endocrine evaluation.

Liver Function

Monitor:

  • AST
  • ALT
  • Bilirubin
  • Other relevant liver biochemical parameters

Monitoring is particularly important in HCC, biliary tract cancer, and combination treatment with tremelimumab.

Renal Function

Monitor serum creatinine, estimated glomerular filtration rate, and electrolytes.

Urinalysis may be appropriate when immune-mediated nephritis is suspected.

Cisplatin-containing regimens require additional renal monitoring.

Blood Glucose

Monitor for hyperglycemia, new insulin deficiency, and diabetic ketoacidosis.

Additional monitoring is important with enfortumab vedotin because hyperglycemia is also an established toxicity of that agent.

Pulmonary Monitoring

Evaluate new or worsening cough, dyspnea, hypoxia, and other respiratory symptoms.

Chest imaging should be obtained when pneumonitis is suspected.

Patients treated with thoracic radiotherapy require particular attention to differentiating immune-mediated and radiation-related pneumonitis.

Gastrointestinal Monitoring

Assess stool frequency, diarrhea, abdominal pain, gastrointestinal bleeding, and dehydration.

Early evaluation of suspected colitis is important, especially with dual checkpoint inhibition.

Cardiovascular Monitoring

Investigate chest pain, palpitations, syncope, or unexplained dyspnea.

ECG, cardiac troponin, echocardiography, or cardiac MRI may be required when myocarditis is suspected.

Neurological Monitoring

Assess new muscle weakness, sensory abnormalities, visual disturbances, confusion, headache, or swallowing difficulties.

Complete Blood Count

Monitor hemoglobin, leukocytes, neutrophils, and platelets.

CBC monitoring is particularly important during chemotherapy-containing treatment.

Combination-Specific Monitoring

Tremelimumab: Gastrointestinal, hepatic, endocrine, and other immune-mediated toxicities.

Cisplatin: Renal function, electrolytes, hearing symptoms, and neuropathy.

Gemcitabine: Myelosuppression, hepatic parameters, and pulmonary symptoms.

FLOT chemotherapy: Blood counts, neuropathy, mucositis, gastrointestinal toxicity, and nutritional status.

Enfortumab vedotin: Skin toxicity, neuropathy, glucose, and ocular symptoms.

BCG: Urinary symptoms, fever, and systemic infection.

Tumor Response

Assess treatment response using appropriate imaging and disease-specific criteria.

Immune-related response patterns may occasionally include pseudoprogression.

However, radiological progression should not automatically be attributed to pseudoprogression.

Perioperative Monitoring

Patients receiving neoadjuvant or adjuvant durvalumab require coordination between oncology and surgical teams.

Assess treatment-related complications that could delay surgery or interfere with postoperative recovery.

Reproductive Monitoring

Verify pregnancy status when clinically appropriate and counsel patients regarding contraception and breastfeeding.

FAQ

What Is Durvalumab Used For?
Durvalumab is used in selected patients with NSCLC, SCLC, biliary tract cancer, HCC, dMMR endometrial cancer, bladder cancer, and resectable gastric or gastroesophageal junction adenocarcinoma.
What Is the Mechanism of Action of Durvalumab?
Durvalumab binds PD-L1 and prevents its interactions with PD-1 and CD80, restoring antitumor T-cell activity.
Is Durvalumab Chemotherapy?
No. Durvalumab is an immune checkpoint inhibitor, although it is frequently combined with chemotherapy.
What Is the Standard Dose?
A commonly used adult dose is 1,500 mg IV, administered every three or four weeks depending on the regimen.

Some indications use different doses or schedules.
How Long Is Durvalumab Treatment?
Duration depends on the indication.

Stage III NSCLC consolidation is generally administered for up to 12 months, while limited-stage SCLC consolidation may continue for up to 24 months.

Advanced cancer treatment commonly continues until progression or unacceptable toxicity.
Is Durvalumab Used After Chemoradiotherapy?
Yes. Durvalumab is approved after concurrent platinum-based chemoradiotherapy in selected patients with unresectable stage III NSCLC and limited-stage SCLC.
Can Durvalumab Be Combined With Tremelimumab?
Yes. The combination is used in unresectable HCC and selected metastatic NSCLC.
Does Durvalumab Require PD-L1 Positivity?
Not for every indication.

Biomarker requirements vary according to the malignancy and geographical region.
Can Durvalumab Treat Bladder Cancer?
Yes. Durvalumab has approved applications in high-risk NMIBC and perioperative MIBC.

Treatment selection depends on disease stage, BCG status, and cisplatin eligibility.
Can Durvalumab Treat Gastric Cancer?
Yes. Durvalumab with perioperative FLOT chemotherapy is approved for eligible patients with resectable gastric or gastroesophageal junction adenocarcinoma.
Can Durvalumab Treat Endometrial Cancer?
Yes. Durvalumab plus carboplatin–paclitaxel followed by durvalumab maintenance is approved for primary advanced or recurrent dMMR endometrial cancer.
Yes. Durvalumab plus carboplatin–paclitaxel followed by durvalumab maintenance is approved for primary advanced or recurrent dMMR endometrial cancer.
Immune-mediated toxicity, which can affect multiple organ systems.
Does Durvalumab Have a Boxed Warning?
No. However, severe and fatal immune-mediated adverse reactions can occur.
How Is Durvalumab Different From Atezolizumab?
Both target PD-L1, but they differ in dosing schedules, approved indications, combination regimens, and pivotal clinical evidence.